Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pulmonology > Sweatman Restrictive Lung Dz and PAH > Flashcards

Sweatman Restrictive Lung Dz and PAH Flashcards

1
Q

name the surfactant agents

A
  1. Poractant
  2. calfactant
  3. beractant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

name the PDE-5inhibitors

A
  1. sildenafil (revatio)

2. tadalafil (adcirca)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Name the immunosupressants for PAH and RLD

A

rituximab, azathioprine, cyclphosphamide and corticosteroids, methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name the long chain fatty acid-derived eicosanoids

A

iloprost, triprostinil, epoprostenol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

name the ET-1 antagonists

A

bosentan and ambrisentan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Name the CCB’s

A

Diltiazem (NONDHP), Nefdipine (DHP), Amlodipine (DHP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

prostacyclin analog

A

treprostinil, iloprost, epoprostenol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

name the three diagnostic categories of restrictive lung disease

A
  1. pneumoconisis
  2. ARDs, NRDS
  3. Idiopathic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

name the 4 types of pneumoconiosis

A
  1. silicosis
  2. beryllosis
  3. CWP
  4. asbestosis
    * review what the inhalant is that cuases the disease in each
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

silicosis predisposes to

A

TB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CWP predisposes to

A

Pulmonary HTN/ right sided heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

mesothelioma predisposes to

A

primary carcinoma of the lung and melignant mesothelioma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

beryllosis predisposes to

A

multi-organ granuloma formation mimicking sarcoidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drugs that can cause ARDS

A

aspirin, opiates, cocaine, phenothiazines, tricyclic antidresessants
*also idiosyncratic reactions with contrast dye and chemotherapeutic agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

alcohol and ARDS

A

does not directly cause ARD but increases the chanes of ARDS from other causes (sepsis and trauma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

most common cause of ARDS

A

Sepsis, Pneumonia, Aspiration, Trauma–> in that order

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

current tx of ARDS (terrible data nothing proven to work)

A

> Beta2 agonists (albuterol), NO–> vasodil. increase perfusion of functioning alveoli
corticosteroids–> antinflamm
prostacycline (PGI2)
Dietary oil supplementation –> antiinflamm..modulate arachadonic acid metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

tx of NRDS in at risk mothers < 34 weeks

A

antenatal corticosteroids–> increases surfactant production and release in the fetus pre-birth, increasing lung function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Aditional tx of NRDS after birth

A

exogenous surfactant to preterm neonates to reduce pulmonary surface tension and improve lung function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

name the exoenous sufactants

A

poractant alfa
calfactant
beractant
*purified animal derivatives rich in surfactant B and C and neutral lipids as well as surface active PL’s (dipalmitoylphosphatidylcholine DPPC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

surface active agent that lowers surface tension

A

dipalmitoyldiphoshatidylcholine DPPC or Lecithin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

multi organ inflammatory dz characterized by non-aseating granulomas in an unspecified foreign body reaciton and peri-hilar bilateral infiltrates

A

sarcoidsosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

tx of sarcoidsosis

A

glucocorticoids to control inflamm.

methotrexate (OFF-LABEL USE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

SIDE EFFECTS OF CHRONIC CORTICOSTEROIDS USE

A

inhibition of hypothalamic-pituitary axis, oseoporosis, pancreatitis, steroid-induced DM, cataracts, glaucoma, pyschosis, oral candidiasis, immunosupression, weight gain, skin atrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Immune effect of chronic steroids
IMMUNE SUPPRESSION-> promote apoptosis of dedritic cells, t cells and macrophages (diminished CMI)
26
methotrexat MOE
DHFRinhibitor-> increase in adenosine mediated immunosupression
27
MTX and adenosine
MTX increases adenosine and causes immunosupresion via adenosine receptors
28
mechanism of MTX and adenosine immunosupression
inhibits AICAR-->FAICAR...AICAR accumulates and inhibits AMP deaminase and Adenosine deaminase--> icnreases adenosine 5'-P and adenosine--> this results in an increase in these products in the extracellular millieu, extracellular adenosine acting via the A2 pathway activated Adnylate cylase, resulting in increased cAMP production in the cell and thus IMMUNOSUPRESSION
29
POTENTIALLY FATALA DVERSE EFFECTS OF METHOTREXATE
ACUTE OR CHRONIC INTERSTITIAL PNEUMONITIS AND PULMONARY FIBROSIS
30
MTX CONTRAINDIATED IN
PT.'S WITH EXISITING IMMUNOSUPRESSION, LUNG DISEASE | CAN CAUSE BIRTH DEFECTS AND MALIGNANT LYMPHOMA
31
IS IPF A chronic inflammatory disease
NO--> EVEN THE MOST POTENT ANTI-INFLAMMATORY DRUGS WILL HAVE LITTLE TO NO EFFECT *15% of interstitial lung disease to which no other cause can be attributed
32
HISTOPATH OF IPF
TEMPORAL HETEROGENEITY
33
SATISFACTORY TX FOR IPF
NONE AT THE MOMENT COMPARED TO PLACEBO (IN FACT SOME DID WORSE) *PATIENTS WITH IPF DO NOT GET THE BENEFIT FROM OTHER DRUGS FOR OTHER FORMS PAH
34
HOW DOES IPF LEAD TO PAH
SHORT-LIVED INFLAMMATORY PRIOCESS LEADS TO PROLIFERATION AND MOBILIZATION OF FIBROLYSIS, apoptosis and a return to normal organ function--> MESNchmye is now altered and leads to altered stromal cell type and activated epithelium-- rlease of TGFb and PDGF--> if capillaries remodeled, PAH will ensue
35
good pasture syndrome is caused by
type II hypersensitivity against alpha3 chain of type IV collagen (anti-GBM disease) of the glomeruli and alveoli anti IgG and anti Igm autoantibodies
36
tx of goodpastures
plasmaphoresis (IVIg)
37
define wegener's
C-ANCA associated autoimune vasculitis of small-medium sized vessels of the upper respiratory tract, lungs and kidney
38
ANCA in wegner's
C anca--> anti-proteinase-3 Anti-neutrophil cytoplasmic antibody
39
Rituximab
minoclonal anti-CD20 antibody
40
MOA for rituximab
induces plasma cell apoptosis via 1. ADCC (recruits macrophages and NK cells by binding to FC receptors of phagocytes and FAB fragement of CD20) 2. CDCC--> generates MAC's on plasma cells 3. INduction of apoptosis directly
41
side effects of rituximab
HTN, asthenia, pruritis, urticaria, rhinitis, arthralgia
42
azathioprine MOA
DNA and RNA synthesis inhibitor--> induces apoptosis in T cell populations
43
azithioprine side effects
neoplastic, mutagenic, leukopenic and thrombocytopenic oxicities, CAN INCREASE RISK OF INFECTION
44
CYCOPHOSPHAMIDE MOA
alkylating agent that also produces B and T cell lymphopenia, selective supression of B lymphocytes activity and decreased Ig secretion
45
side effects of cyclophosphamide
hemorrhagic cystitis--> MESNA is prophylacitc neutro thrombocytopenias bladder cancer myeloproliferative or lymphoproliferative malignancies
46
Only drug used for systemic HTn that also works partially in PAH
CCB's
47
pathogenesis of PAH
decrease in production of PGI2 and NO increase in production of Endothelin 1 and TXA2 (more pronounced presence) *leading to smooth muscle and endothelial cell proliferation, propagation and hypertrophy (thanks to growth inhibitors and mitogenic factors--> eventually fibrosis and thrombosis
48
resultant of PAH and sheer stress
pexiform lesions (more common in females)
49
PLEXIFORM LESION ETIOLOGY
PULMONARY ARTERY ENDOTHELIAL DAMAGE--> proliferation of monoclonal endothelial cells smooth muscles and accumulation of circulating cells (macrophages)--> lead to SIGNIFICANT OUTFLOW OBSTRUCTION
50
PGI2 CAUSES WHAT normally
inhibits platelet activation and smooth muscle growth
51
endothelin also causes what normally
smooth muscle growth
52
absence of PGI2 has what effect on TXA2
now allows TXA2 to act unchecked leading to improper platelet aggregation
53
NO usually has what effect in the lungs
inhibits platelet activation and inhibits smooth muscle cell growth
54
PGI2 causes what effect on blood vessels
increase cAMP and causes vasodilation
55
NO is made from what precursor and turns into what
L-arginine--> cGMP
56
effect of NO on blood vessels
turns L-arginine into NO--> increase cGMP--> leading to vasodilaiton and antiproliferaiton
57
endothelin ahs what effect on the pulmonary blood vessels
vasoconstriction and muscle cell proliferaiton
58
depletion of B cells by rituximab lasts how long
6-9 mos following 3 doses
59
MOA for all prostanoids
induce PAvasodilation, retard smooth muscle growth and disrupts platelet aggregation
60
rout of epoprostenol
requires constant IV infusion (half life=5 minutes)
61
epoprosternol AE's
hypotension, flushing, headaches, bleeding if anticoagulated, catheter infection
62
Iloprost route
6-9 inhaled doses daily (half life 25 minutes) 10 minutes per dose
63
Iloprost AE's
hemoptysis (MUST MONITOR), flushing, cough, headaches-most common *hypotension, tongue/back pains, minotor for bleeding
64
Treprostinil route
continuous SC infusion half life 4 hours or IV infusion (more stable
65
AE associated with treprostinil
injection site erythema, rash headache, nasue/ diarrhea, --> MONITOR FOR BLEEDING - -> CYP 2C8 D-D INTRXNS - ->DEC CLEARANCE WITH GEMFIBROZIL - -> INCREASED CLEARANCE WITH RIFAMPIN
66
ET1 ANTAGONISTS MOA
block smooth muscle proliferation signal and pulmonary arterial vasocnstriction produced by ET1 binding to ET-1 TYPE A RECEPTORS AND TYPE B RECEPTORS
67
ET1-A RECEPTORS ARE LOCATED WHERE
SMOOTH MUSCLE
68
ET1-B RECEPTORS ARE LOCATED WHERE
ENDOTHELIAL CELLS (BLOOD VESSELS)
69
ADVANTAGE OF ET1 ANTAGONISTS
ORALLY AVAILABLE, EASIER DOSING
70
DISDVANTAGES OF ET1 ANTAGONISTS
EXPENSIVE AND CATEGORY X (MAJOR TERATOGENS)
71
BOSENTAN ALSO ASSOCIATED WITH
LIVER AND BLOOD TOXICITIES
72
HALF LIVES OF ET1 ANTAGS
BOSENTAN --> 5-8HRS BID *HEPATOTOXICITY | AMBRISENTAN--> 15 HOURS QD
73
CYPS INVOLEVED WITH ET1 ANTAGS
CYP 3a4 and CYP 2c9 | ambrisenten is a substrate and inhibitor if pgp as well as OATP
74
PDE 5 inhibitors--> MOA
perpetuate endogenous cGMP leading to vasodilation and reduce deulluar proliferation
75
PDE5 inhibitors should not be taken in pt.'s taking
organic nitrates such as NITROGLYCERINE FOR ANGINA
76
name the PDE5 inhibitors
sildenafil (3-4 hours), tadalafil (17 hours)
77
major side effects of sildenafil and tadalafil
S--> epistaxis, dizziness, hearing loss | T--> change in color vision,back pain dyspepsia,
78
CCB MOA
prevent calcium from entering cell and inhibit SM vasoconstrcition--> cause vasorelaxation--> dec blod pressure
79
vasodilation challenge--> ONLY 15% of patient are candiates for CCB therapy due to negative vasodilaiton challeneg
IV epoprostenol, IV adenosine, and inhaled NO--> measure CO and PAP for 3 hours...if PAP goes down without a decrease in CO
80
do CCB's improve mortality
yes--> but dont work in everyone and can lead to CV collapse
81
name the ccb's and their major side effects
diltiazem-> bradycard, hypotension nefedipine--> flushing, edema, hypotension, heartburn amlodipine--> edema, fatigue, hypotension
82
CCB avoided in PAH
verapamil--> negative inotropic effect
83
goal of CCB therapy...
get the pt. back to functional class 1 or 2 by 3-4 mos...if not achieved..consider alternative therapy

Pulmonology (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions